-
A 66-year-old postmenopausal retired teacher went to her primary care physician because she found a lump in her right breast during a routine bath.
-
In a large multi-institutional prospective trial conducted from 1994-2001, 1979 eligible patients (median age 70 years) with PSA < 20 were randomized to radiation therapy alone or radiotherapy plus 4 months of total androgen suppression starting 2 months before radiotherapy.
-
Fourteen elderly patients (median age 85 years) who were considered non-candidates for R-CHOP were treated first-line with a combination of bendamustine and rituximab. Of these, 7 achieved a complete response and 2 achieved a partial response. Toxicity was minimal. Although promising, these results need to be confirmed in larger studies.
-
-
Apixaban could soon join the anticoagulation market; Chinese herbs for flu; chronic medication and discontinuation after hospitalization; and FDA actions.
-
For patients in the midst of chemotherapy, there are little data on the most efficacious time to administer influenza vaccine. In a randomized study of 38 patients receiving FEC chemotherapy for adjuvant treatment of breast cancer, it is apparent that vaccination early (on day 4 of a 21-day cycle) provided better antibody response than when administered late in the cycle (day 16).
-
A 70-year-old man undergoing preoperative evaluation for abdominal aortic aneurysm surgery was noted to have a 3 cm mass in the right adrenal gland with heterogeneous texture but clear margins.
-
The prognostic relevance of fms-like tyrosine kinase 3 (FLT3) internal tandem duplications and point mutations at D835 in acute promeylocytic leukemia (APL) is controversial.
-
A 78-year-old man was referred for evaluation and treatment of recently discovered glioblastoma. While dining with his children he collapsed from his chair and was observed to have a grand mal seizure. He had transiently lost consciousness and when he awoke he had weakness in both upper and lower extremities on the right side.
-
In a review of nine Phase 3 trials enrolling 6,284 patients, data from 793 who were younger than 50 years old were compared to the remainder who were older than 50 years, with attention given to progression-free survival, response rates, and overall survival.
